arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Tectonic Therapeutic, Inc.

TECX Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$30.75
Today
as of Sep 4, 16:55 ET
Last 30 days +3.19% Jul 28 → Sep 04
$27.14 $29.98 $32.81 $35.65 $38.49 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$29.85
High
$31.12
Low
$29.73
Volume
$159,288
Avg Vol
$336,714
Mkt Cap
$664M
P/E (TTM)
—
Beta
—
52w High
$39.53
52w Low
$14.39
Div Yield
—
Shares Out
$19M

Recent Press Releases & News last 60 days · 2 items

Sep 3 · 12:00 PR GlobeNewswire
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
Aug 6 · 20:01 PR GlobeNewswire
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

Overview

52-week range
$14
$40
65% of range
Avg surprise (last 3)
-3.1%
Avg reaction (last 2)
+1.7%
50% positive
Latest IV / EM
117%
EM ±18.2% · $30 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-10.97$-8.37$-5.77$-3.17$-0.57 Actual $-0.57Actual $-8.51Actual $-7.62Actual $-10.97Actual $-4.34Actual $-1.20Actual $-0.93Est $-1.10Actual $-1.07Est $-0.98Actual $-1.02Actual $-1.34Est $-1.16Actual $-1.18 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-25M$-23M$-21M$-19M$-17M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.18 — — — — financials
Thu May 7, 2026Mar/2026 $-1.34 $-1.16 -15.5% -44.1% -7.4% earnings
Tue Sep 30, 2025Sep 2025 $-1.02 — — — — financials
Thu Aug 7, 2025Jun/2025 $-1.07 $-0.98 -9.2% — — earnings
Thu May 8, 2025Mar/2025 $-0.93 $-1.10 +15.4% — +10.8% earnings
Mon Sep 30, 2024Sep 2024 $-1.20 — — — — financials
Sun Jun 30, 2024Jun 2024 $-4.34 — — — — financials
Sun Mar 31, 2024Mar 2024 $-10.97 — — — — financials
Sat Sep 30, 2023Sep 2023 $-7.62 — — — — financials
Fri Jun 30, 2023Jun 2023 $-8.51 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.57 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-24M$-27M—$-22M$-22M$-18M—$-20M
Net income$-22M$-25M—$-19M$-20M$-16M—$-18M
EPS (diluted)$-1.18$-1.34—$-1.02$-1.07$-0.93—$-1.20

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$227M$237M$254M$268M$287M$306M$141M$159M
Inventory————————
Total current assets$231M$240M$257M$273M$291M$310M$147M$163M
Total assets$237M$247M$261M$277M$295M$315M$153M$169M
Long-term debt————————
Total liabilities$13M$16M$10M$9M$12M$14M$12M$18M
Total equity$224M$230M$251M$268M$284M$301M$141M$150M

Implied volatility — last 90 days

90%170%251%332%412% Jun 07 — IV 133% · EM ±18.4%Jun 08 — IV 137% · EM ±18.0%Jun 09 — IV 159% · EM ±20.0%Jun 10 — IV 134% · EM ±15.9%Jun 11 — IV 130% · EM ±14.3%Jun 12 — IV 165% · EM ±16.9%Jun 15 — IV 212% · EM ±15.3%Jun 16 — IV 257% · EM ±15.2%Jun 17 — IV 394% · EM ±16.5%Jun 19 — IV 102% · EM ±22.6%Jun 22 — IV 105% · EM ±21.9%Jun 23 — IV 104% · EM ±21.2%Jun 24 — IV 93% · EM ±18.6%Jun 25 — IV 104% · EM ±20.4%Jun 26 — IV 121% · EM ±23.1%Jun 29 — IV 116% · EM ±20.6%Jun 30 — IV 99% · EM ±17.0%Jul 01 — IV 155% · EM ±26.0%Jul 02 — IV 105% · EM ±17.0%Jul 03 — IV 155% · EM ±24.3%Jul 06 — IV 129% · EM ±17.8%Jul 07 — IV 160% · EM ±21.1%Jul 08 — IV 121% · EM ±15.2%Jul 09 — IV 124% · EM ±14.6%Jul 10 — IV 134% · EM ±14.8%Jul 13 — IV 165% · EM ±13.8%Jul 14 — IV 138% · EM ±10.0%Jul 15 — IV 390% · EM ±23.1%Jul 16 — IV 413% · EM ±17.2%Jul 20 — IV 116% · EM ±27.4%Jul 21 — IV 108% · EM ±25.1%Jul 22 — IV 122% · EM ±27.9%Jul 23 — IV 113% · EM ±25.3%Jul 24 — IV 112% · EM ±24.9%Jul 27 — IV 124% · EM ±26.0%Jul 28 — IV 113% · EM ±23.2%Jul 29 — IV 116% · EM ±23.2%Jul 30 — IV 125% · EM ±24.4%Jul 31 — IV 100% · EM ±19.1%Aug 03 — IV 114% · EM ±20.1%Aug 04 — IV 109% · EM ±18.8%Aug 05 — IV 124% · EM ±20.6%Aug 06 — IV 124% · EM ±20.1%Aug 07 — IV 117% · EM ±18.2%Aug 10 — IV 179% · EM ±24.8%Aug 11 — IV 175% · EM ±23.1%Aug 12 — IV 125% · EM ±15.6%Aug 13 — IV 129% · EM ±15.2%Aug 14 — IV 135% · EM ±14.9%Aug 17 — IV 179% · EM ±14.9%Aug 18 — IV 204% · EM ±14.8%Aug 19 — IV 265% · EM ±15.7%Aug 20 — IV 329% · EM ±13.7%Aug 24 — IV 120% · EM ±25.1%Aug 25 — IV 130% · EM ±26.6%Aug 26 — IV 108% · EM ±21.5%Aug 27 — IV 125% · EM ±24.5%Aug 28 — IV 116% · EM ±22.2%Aug 31 — IV 101% · EM ±17.9%Sep 01 — IV 90% · EM ±15.5%Sep 02 — IV 117% · EM ±19.6%Sep 03 — IV 102% · EM ±16.5%Sep 04 — IV 117% · EM ±18.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in